- Home
- BVN vs CRSP Comparison
BVN vs CRSP Comparison
Compare BVN & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BVN
- CRSP
- Stock Information
- Founded
- BVN 1953
- CRSP 2013
- Country
- BVN Peru
- CRSP Switzerland
- Employees
- BVN N/A
- CRSP N/A
- Industry
- BVN Metal Mining
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BVN Basic Materials
- CRSP Health Care
- Exchange
- BVN Nasdaq
- CRSP Nasdaq
- Market Cap
- BVN 3.1B
- CRSP 3.3B
- IPO Year
- BVN 1996
- CRSP 2016
- Fundamental
- Price
- BVN $15.01
- CRSP $35.62
- Analyst Decision
- BVN Buy
- CRSP Buy
- Analyst Count
- BVN 2
- CRSP 17
- Target Price
- BVN $16.75
- CRSP $74.53
- AVG Volume (30 Days)
- BVN 1.1M
- CRSP 2.0M
- Earning Date
- BVN 05-01-2025
- CRSP 05-06-2025
- Dividend Yield
- BVN 1.87%
- CRSP N/A
- EPS Growth
- BVN 1928.16
- CRSP N/A
- EPS
- BVN 1.90
- CRSP N/A
- Revenue
- BVN $1,215,528,000.00
- CRSP $37,675,000.00
- Revenue This Year
- BVN N/A
- CRSP $51.35
- Revenue Next Year
- BVN N/A
- CRSP $282.16
- P/E Ratio
- BVN $7.90
- CRSP N/A
- Revenue Growth
- BVN 40.15
- CRSP N/A
- 52 Week Low
- BVN $11.50
- CRSP $30.04
- 52 Week High
- BVN $18.84
- CRSP $67.88
- Technical
- Relative Strength Index (RSI)
- BVN 54.72
- CRSP 44.74
- Support Level
- BVN $14.67
- CRSP $33.03
- Resistance Level
- BVN $15.46
- CRSP $39.38
- Average True Range (ATR)
- BVN 0.51
- CRSP 1.81
- MACD
- BVN 0.05
- CRSP -0.19
- Stochastic Oscillator
- BVN 77.50
- CRSP 33.64
About BVN Buenaventura Mining Company Inc.
Compania de Minas Buenaventura SAA is a Peruvian precious metals-producing company with experience in mine exploration, development, construction, and operation.
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.